Thursday, June 11, 2026

Patent directory Β· USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,769
Drugs linked 4,797

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code β€” or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 44 of 1,261
  1. US 12291576

    Anti-CD45 antibodies and conjugates thereof

    Vor Biopharma Inc. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  2. US 12292445

    Methods of selecting subjects for treatment with metabolomic modulators

    The Regents of the University of California Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  3. US 12290524

    Methods and compositions for testosterone production

    Maximus Health, Inc. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  4. US 12291565

    Tau binding compounds

    VOYAGER THERAPEUTICS, INC. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  5. US 12291557

    Chimeric TIM4 receptors and uses thereof

    Cero Therapeutics Holdings, Inc. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  6. US 12291560

    Dimerizing agent regulated immunoreceptor complexes

    REGENERON PHARMACEUTICALS, INC. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  7. US 12290566

    Dosing regimens and related compositions and methods

    Apellis Pharmaceuticals, Inc. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  8. US 12291507

    Compounds and their use for the treatment of ALPHA1-antitrypsin deficiency

    CENTESSA PHARMACEUTICALS (UK) LIMITED Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  9. US 12291709

    Compositions and methods for modulating apolipoprotein (a) expression

    Ionis Pharmaceuticals, Inc. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  10. US 12290505

    Tissue factor-targeted antibody-drug conjugate

    SHANGHAI MIRACOGEN INC. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  11. US 12291556

    Parathyroid hormone variants

    Takeda Pharmaceutical Company Limited Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  12. US 12290531

    Compositions targeting BCMA and methods of use thereof

    Takeda Pharmaceutical Company Limited Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  13. US 12290597

    Oral film compositions and dosage forms having precise active dissolution profiles

    Aquestive Therapeutics, Inc. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  14. US 12291548

    Compounds, compositions, and methods for the treatment of disease

    Sperovie Biosciences, Inc. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  15. US 12290573

    Modified RNAi agents

    Alnylam Pharmaceuticals, Inc. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  16. US 12290069

    Pest control using natural pest control agent blends

    TYRATECH, INC. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  17. US 12291559

    Compositions and methods for treating cancer

    REGENERON PHARMACEUTICALS, INC. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  18. US 12291571

    Methods for reducing eosinophilic infiltration by administering an anti-interleukin-4 receptor (IL4R) antibody

    REGENERON PHARMACEUTICALS, INC. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  19. US 12291533

    Substituted fused pyrimidine compounds and uses thereof

    Northwestern University Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  20. US 12291508

    Hydrazide containing nuclear transport modulators and uses thereof

    Karyopharm Therapeutics Inc. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  21. US 12290538

    Methods and products for treatment of gastrointestinal disorders

    Finch Therapeutics Holdings LLC Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  22. US 12290551

    Methods for imaging and treatment of somatostatin-receptor positive tumors

    Corcept Therapeutics Incorporated Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  23. US 12290588

    Peptide having activity of improving skin condition and use thereof

    CAREGEN CO., LTD. Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted
  24. US 12290569

    Methods and compositions using peptides and proteins with c-terminal elements

    SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE Β· Granted May 6, 2025 Β· Expires May 1, 2045

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search β€” best for looking up a specific filing or applicant portfolio slice.